



Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes

Bjorgvinsdottir, Unnur Jona; Carstensen, Laura Stentoft; Colliander, Anna; Jaehger, Ditte Elisabeth; Veiga, Gael Clergeaud; Halldorsdottir, Holmfriour Rosa; Jorgensen, Matilde Smaerup; Christensen, Esben; Vangsgaard, Sara; Koukos, Aristeidis

Total number of authors:
13

Published in:
Journal for ImmunoTherapy of Cancer

Link to article, DOI:
[10.1136/jitc-2021-SITC2021.771](https://doi.org/10.1136/jitc-2021-SITC2021.771)

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Bjorgvinsdottir, U. J., Carstensen, L. S., Colliander, A., Jaehger, D. E., Veiga, G. C., Halldorsdottir, H. R., Jorgensen, M. S., Christensen, E., Vangsgaard, S., Koukos, A., Bak, M., Kempen, P., & Andresen, T. L. (2021). Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes. *Journal for ImmunoTherapy of Cancer*, 9(Suppl. 2), A806-A806. <https://doi.org/10.1136/jitc-2021-SITC2021.771>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

NOVEL LIPID NANOPARTICLE VACCINE PLATFORM FOR EFFICIENT DELIVERY OF HIGH- AND LOW-AFFINITY EPITOPES

¹Unnur Jóna Björngvinsdóttir*, ²Laura Stentoft Carstensen*, ¹Anna Colliander, ¹Ditte Elisabeth Jæhger, ¹Gael Clergeaud Veiga, ¹Hólmfríður Rósa Halldórsdóttir, ¹Matilde Smærup Jørgensen, ¹Esben Christensen, ¹Sara Vangsgaard, ¹Aristeidis Koukos, ¹Martin Bak, ¹Paul Kempen, ¹Thomas Lars Andresen. ¹Technical University of Denmark, Lyngby, Denmark; ²Technical University of Denmark, Lyngby, Denmark

Background Therapeutic cancer vaccines represent an intriguing approach to cancer immunotherapy and they have been widely explored for the last decade. As opposed to standard modalities, such as surgery and chemotherapy, an effective vaccine-based immune response may provide protection against metastatic disease. Peptide based vaccines can elicit a highly targeted immune response and include a simple, fast and cost-effective production due to recent developments in solid phase peptide synthesis. Recent development within the field of COVID-19 vaccines has highlighted the use of lipid nanoparticles as an effective drug delivery system for vaccination. Incorporation of peptide antigens into engineered micro- and nanoparticles enables induction of a potent T cell response, partly attributed to prolonged and improved antigen presentation by dendritic cells after particle internalization. Peptide-based vaccines are often based on delivery of high-affinity T cell model epitopes. However, the therapeutic relevance of vaccination with low-affinity epitopes is gaining increasing support following the observation that high-affinity epitopes can promote T cell exhaustion resulting from excessive T cell receptor stimulation. Here, we characterize and evaluate a novel lipid nanoparticle (LNP) vaccine platform that is suited for delivery of both high- and low-affinity epitopes in the setting of therapeutic cancer vaccination.

Methods LNPs were formulated to carry high- or low-affinity peptide epitopes from Ovalbumin (OVA) in conjunction with the TLR7 agonist 1V270. The peptides were anchored to the surface of the LNPs via a reducible DSPE-PEG2000 linker system. The therapeutic vaccine platform was evaluated in vivo both as a monotherapy and in combination with adoptive transfer of OT-I T cells in the syngeneic B16-OVA murine melanoma model.

Results The LNP vaccine promotes efficient antigen-release and ensures high, continuous antigen-presentation by antigen-presenting cells. While the LNPs can be administered via multiple routes, intratumoral vaccination favors enhanced particle uptake in dendritic cells in the tumor. Formulated with either high- or low-affinity epitopes, intratumorally delivered vaccine particles promote superior tumor-infiltration of adoptively transferred T cells, which translates into potent anti-tumor efficacy in vivo. Finally, we show that vaccination with both CD8+ and CD4+ epitopes can delay tumor growth and prolong survival in an antigen-dependent manner.

Conclusions This study presents a versatile and multi-purpose LNP vaccine platform that ensures effective delivery of high- and low-affinity epitopes. Intratumoral administration promotes vaccine particle uptake by intratumoral dendritic cells, which is followed by T cell infiltration and anti-tumor efficacy in vivo.

Ethics Approval All animal procedures were approved by the Danish National Animal Experiments Inspectorate.

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.771>